title: T cells as a therapeutic target in SLE.
abstract: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by a loss of tolerance to multiple endogenous antigens. SLE etiology remains largely unknown, despite recent insight into the immunopathogenesis of the disease. T cells are important in the development of the disease by amplifying the immune response and contributing to organ damage. Aberrant signaling, cytokine secretion, and tissue homing displayed by SLE T cells have been extensively studied and the underlying pathogenic molecular mechanisms are starting to be elucidated. T-cell-targeted treatments are being explored in SLE patients. This review is an update on the T-cell abnormalities and related therapeutic options in SLE.
authors: Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland dcomte@bidmc.harvard.edu.
authors: D
authors: D
authors: Comte
authors: Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors: M P
authors: MP
authors: Karampetsou
authors: Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors: G C
authors: GC
authors: Tsokos
mesh_terms: D000818:Animals; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000276:immunology; D044127:Epigenesis, Genetic; D006801:Humans; D007108:Immune Tolerance; D007376:Interleukin-2 / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy*; D015398:Signal Transduction / Q000235:genetics; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D061025:Costimulatory and Inhibitory T-Cell Receptors; D007376:Interleukin-2
keywords: Systemic lupus erythematosus; T cells; epigenetics; interleukin-2 (IL-2); treatment